Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.

Elsby R, Hare V, Neal H, Outteridge S, Pearson C, Plant K, Gill RU, Butler P, Riley RJ.

Drug Metab Dispos. 2019 Jan;47(1):1-8. doi: 10.1124/dmd.118.083832. Epub 2018 Oct 22.

PMID:
30348903
3.

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.

Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, Oliver S, Holmes V, Severin P, Elsby R.

Drugs R D. 2016 Mar;16(1):93-107. doi: 10.1007/s40268-015-0120-x.

4.

Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.

Elsby R, Martin P, Surry D, Sharma P, Fenner K.

Drug Metab Dispos. 2016 Mar;44(3):398-408. doi: 10.1124/dmd.115.066795. Epub 2015 Dec 23.

PMID:
26700956
5.

Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.

Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, Baluom M, Lau D, Mant T.

Clin Ther. 2015 Dec 1;37(12):2811-22. doi: 10.1016/j.clinthera.2015.09.018. Epub 2015 Oct 26.

PMID:
26514315
6.

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ.

Eur J Clin Pharmacol. 2015 Mar;71(3):341-55. doi: 10.1007/s00228-014-1801-z. Epub 2015 Feb 12.

PMID:
25673568
7.

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.

Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ.

Eur J Clin Pharmacol. 2015 Mar;71(3):329-40. doi: 10.1007/s00228-014-1800-0. Epub 2015 Jan 30.

PMID:
25630984
8.

The use of bioreactors as in vitro models in pharmaceutical research.

Ginai M, Elsby R, Hewitt CJ, Surry D, Fenner K, Coopman K.

Drug Discov Today. 2013 Oct;18(19-20):922-35. doi: 10.1016/j.drudis.2013.05.016. Epub 2013 Jun 5. Review.

PMID:
23748137
9.

Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, Bai JP, Polli JW, Sugiyama Y, Brouwer KL; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):126-41. doi: 10.1038/clpt.2013.78. Epub 2013 Apr 10. Review.

10.

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

Elsby R, Hilgendorf C, Fenner K.

Clin Pharmacol Ther. 2012 Nov;92(5):584-98. doi: 10.1038/clpt.2012.163. Epub 2012 Oct 10. Review.

PMID:
23047648
11.

Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.

Sharma P, Butters CJ, Smith V, Elsby R, Surry D.

Eur J Pharm Sci. 2012 Aug 30;47(1):244-55. doi: 10.1016/j.ejps.2012.04.003. Epub 2012 Apr 19.

PMID:
22538052
12.

The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus.

Elsby R, Heiber JF, Reid P, Kimball SR, Pavitt GD, Barber GN.

J Virol. 2011 Oct;85(19):9716-25. doi: 10.1128/JVI.05146-11. Epub 2011 Jul 27.

13.

Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

Elsby R, Smith V, Fox L, Stresser D, Butters C, Sharma P, Surry DD.

Xenobiotica. 2011 Sep;41(9):764-83. doi: 10.3109/00498254.2011.578761. Epub 2011 May 25.

PMID:
21612343
14.

In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.

Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V, Surry D.

Eur J Pharm Sci. 2011 May 18;43(1-2):41-9. doi: 10.1016/j.ejps.2011.03.006. Epub 2011 Apr 1.

PMID:
21440623
15.

The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.

Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD.

Drug Metab Dispos. 2011 Feb;39(2):275-82. doi: 10.1124/dmd.110.035881. Epub 2010 Nov 12.

PMID:
21075975
16.

Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

Sharma P, Holmes VE, Elsby R, Lambert C, Surry D.

Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013.

PMID:
19919292
17.
18.

NFAR-1 and -2 modulate translation and are required for efficient host defense.

Pfeifer I, Elsby R, Fernandez M, Faria PA, Nussenzveig DR, Lossos IS, Fontoura BM, Martin WD, Barber GN.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4173-8. doi: 10.1073/pnas.0711222105. Epub 2008 Mar 12.

19.

Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses.

Venkataraman T, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S, Iwakura Y, Barber GN.

J Immunol. 2007 May 15;178(10):6444-55.

20.

Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags.

Jenkins RE, Kitteringham NR, Hunter CL, Webb S, Hunt TJ, Elsby R, Watson RB, Williams D, Pennington SR, Park BK.

Proteomics. 2006 Mar;6(6):1934-47.

PMID:
16479536
21.

Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice.

Goldring CE, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, McMahon M, Hayes JD, Itoh K, Yamamoto M, Park BK.

Hepatology. 2004 May;39(5):1267-76.

PMID:
15122755
22.

Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi.

Elsby R, Kitteringham NR, Goldring CE, Lovatt CA, Chamberlain M, Henderson CJ, Wolf CR, Park BK.

J Biol Chem. 2003 Jun 20;278(25):22243-9. Epub 2003 Mar 19.

23.

Protein expression profiling of glutathione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol-induced toxicity in the liver.

Kitteringham NR, Powell H, Jenkins RE, Hamlett J, Lovatt C, Elsby R, Henderson CJ, Wolf CR, Pennington SR, Park BK.

Proteomics. 2003 Feb;3(2):191-207.

PMID:
12601812
24.
25.
26.

Obstacles to the prediction of estrogenicity from chemical structure: assay-mediated metabolic transformation and the apparent promiscuous nature of the estrogen receptor.

Elsby R, Ashby J, Sumpter JP, Brooks AN, Pennie WD, Maggs JL, Lefevre PA, Odum J, Beresford N, Paton D, Park BK.

Biochem Pharmacol. 2000 Nov 15;60(10):1519-30.

PMID:
11020455

Supplemental Content

Support Center